Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
Am J Med Sci
; 360(3): 216-221, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-457538
ABSTRACT
The potentially lethal infection caused by the novel Severe Acute Respiratory Disease Coronavirus-2 (SARS-CoV-2) has evolved into a global crisis. Following the initial viral infection is the host inflammatory response that frequently results in excessive secretion of inflammatory cytokines (e.g., IL-6 and TNFα), developing into a self-targeting, toxic "cytokine storm" causing critical pulmonary tissue damage. The need for a therapeutic that is available immediately is growing daily but the de novo development of a vaccine may take years. Therefore, repurposing of approved drugs offers a promising approach to address this urgent need. Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFα, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries. Furosemide is a "repurpose-able" small molecule therapeutics, that is safe, easily synthesized, handled, and stored, and is available in reasonable quantities worldwide.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
/
Furosemide
/
Immunity, Innate
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Am J Med Sci
Year:
2020
Document Type:
Article
Affiliation country:
J.amjms.2020.05.044
Similar
MEDLINE
...
LILACS
LIS